Treatment of retained placenta with misoprostol: a randomised controlled trial in a low-resource setting (Tanzania). by Beekhuizen, H.J. van et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/81068
 
 
 
Please be advised that this information was generated on 2017-12-06 and may be subject to
change.
BMC Pregnancy and Childbirth BioMed Central
Open AccessStudy protocol
Treatm ent of retained placenta with misoprostol: a randomised 
controlled trial in a low-resource setting (Tanzania)
Heleen J van Beekhuizen*1, Andrea B Pem be2, Heiner Fauteck3 and 
Fred K Lotgering4
Address: 'D epartm ent o f Obstetrics and Gynaecology, Erasmus Medical Centre, PO box 2040, 3000 CA Rotterdam, The Netherlands, 2Departm ent 
o f Obstetrics and Gynaecology, M uhim bili University o f Health and Allied Sciences, Dar es Salaam, Tanzania, 3Institute for Cancer Epidemiology, 
University Luebeck, Germany and 4Departm ent o f Obstetrics and Gynaecology, Radboud University Nijmegen Medical Centre, Nijmegen, The 
Netherlands
Email: Heleen J van Beekhuizen* - Heleen@ airpost.net; Andrea B Pembe - andreapem be@ yahoo.co.uk;
Heiner Fauteck - heiner.fauteck@ web.de; Fred K Lotgering - F.Lotgering@obgyn.umcn.nl
* Corresponding author
Published: 23 O ctober 2009 Received: 5 July 2009
BMC Pregnancy and Childbirth 2009, 9:48 d o i:l0 .l 186/1471 -2393-9-48 AccePted: 23 ° ct° ber 2009 
This article is available from : http://www.biom edcentral.cOm /l47l-2393/9/48  
©  2009 van Beekhuizen et al; licensee BioMed Central Ltd.
This is an Open Access article distributed under the terms of the Creative Commons A ttribu tio n  License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original w o rk  is properly cited.
Abstract
Background: Retained placenta is one of the common causes of maternal mortality in developing countries 
where access to appropriate obstetrical care is limited. Current treatment of retained placenta is manual removal 
of the placenta under anaesthesia, which can only take place in larger health care facilities. Medical treatment of 
retained placenta with prostaglandins El (misoprostol) could be cost-effective and easy-to-use and could be a life- 
saving option in many low-resource settings. The aim of this study is to assess the efficacy and safety of sublingually 
administered misoprostol in women with retained placenta in a low resource setting.
Methods: Design: Multicentered randomised, double-blind, placebo-controlled trial, to be conducted in 5 
hospitals in Tanzania, Africa.
Inclusion criteria: Women with retained placenta, at a gestational age of 28 weeks or more and blood loss less 
than 750 ml, 30 minutes after delivery of the newborn despite active management of third stage of labour.
Trial Entry & Randomisation & Study Medication: After obtaining informed consent, eligible women will be 
allocated randomly to the treatment groups using numbered envelopes that will be randomized in variable blocks 
containing identical capsules with either 800 microgram of misoprostol or placebo. The drugs will be given 
sublingually. The women, maternal care providers and researchers will be blinded to treatment allocation.
Sample Size: l l7  women, to show a 40% reduction in manual removals of the placenta (p = 0.05, 80% power). 
The randomization will be misoprostol: placebo = 2: l
Primary Study Outcome: Expulsion of the placenta without manual removal. Secondary outcome is the number 
of blood transfusions.
Discussion: This is a protocol for a randomized trial in a low resource setting to assess if medical treatment of 
women with retained placenta with misoprostol reduces the incidence of manual removal of the placenta.
Clinical Trial Registration: Current Controlled Trials ISRCTNl6l04753
Page 1 of 6
(page number not for citation purposes)
BMC Pregnancy and Childbirth 2009, 9:48 http://www.biomedcentral.eom/1471 -2393/9/48
Background
Retained placenta: diagnosis, definition and the burden o f  
disease
The diagnosis 'retained placenta' (RP) is established when 
the placenta is not expelled after a certain time period fol­
lowing the delivery of the infant[1,2]. The time period in 
the definition of RP varies among countries. In our study 
location Tanzania, like most English speaking countries, 
RP is defined as lack of expulsion of the placenta 30 m in­
utes after delivery of the infant [3], while in other coun­
tries the diagnosis RP is only made after 60 minutes 
postpartum [4]. Complications of RP are postpartum 
haemorrhage and infection[5], which may both lead to 
maternal morbidity and mortality. The need to improve 
maternal mortality has been recognized at a global level 
by including it in the Millennium Development Goals [6].
Tanzania is a low resource country with a high maternal 
mortality rate. It is estimated that 578 women per 
100,000 live-births die as a result of pregnancy-related 
complications [7]. A retrospective study in Tanzania 
showed that RP contributed by 13% to the maternal 
deaths [8]. The morbidity due to RP is mainly caused by 
infections and anaemia. A study by Tandberg et al found 
a significant fall in haemoglobin level postpartum com­
pared to antepartum by a m ean of 3.4 g/dl (2.1 mmol/l) 
in the RP group as compared to no significant change in 
the controls; blood transfusion was required in 10% of 
the RP group versus 0.5% in the control group [9].
Retained Placenta: incidence
The incidence of RP is approximately 1-2% of all deliver­
ies worldwide, the exact data for Tanzania is no t known. 
The reported incidence of RP is affected by the following 
four factors: definition of the time interval [4], gestational 
age, an obstetrical history of previous RP or not, and the 
presence or absence of active management of the third 
stage of labour (AMTSL).
The incidence of RP in an unselected group of nulliparous 
women in The Netherlands was 6.3% at 30 minutes and
1.8% at 60 minutes after delivery of the newborn [4]. The 
incidence of RP, 30 minutes after delivery of the newborn 
has been reported as 8% in preterm and 1.1% in term 
deliveries [10]. The recurrence risks of RP reported in two 
studies of parous women were 16% and 23% [9,11]. A 
randomized controlled trial (RCT) showed that AMTSL 
reduced the incidence of RP (after 30 minutes) to 1.6% as 
compared to 4.6% in the control group [12].
Retained placenta: how can w e prevent maternal 
mortality?
Blood loss associated with RP can be acute life-threaten­
ing and requires emergency interventions like administra­
tion of uterotonics, correction of hypovolaemia by
administration of intravenous fluids, manual removal of 
the placenta (MRP) under anaesthesia and blood transfU- 
sions[13]. All these interventions need skilled personnel 
and equipment. In many low-resource countries women 
deliver at home, and the nearest health care facility often 
lacks drugs and equipm ent to perform MRP or to give 
blood transfusion, leaving the midwife empty-handed. 
Transport to health care facilities with comprehensive 
emergency obstetrical care requires time and money, both 
are limited commodities in those circumstances [6,8]. 
Medical treatment of RP with an easy-to-administer drug 
could save the life of patients under those circumstances.
Retained placenta: medical treatment with prostaglandin 
analogues
Medical treatment of RP includes the administration of 
oxytocin in the umbilical vein, which was reported to be 
effective in one out of eight women (relative risk 0.79, 
95% CI 0.69-0.91) [14]. The disadvantage of this method 
in low resource settings is that it requires skilled medical 
personnel and equipment.
A RCT in The Netherlands showed that administration of 
250 microgram prostaglandin E2 (sulprostone) intrave­
nously 60 minutes after delivery of the infant effectively 
expelled 49% of RP versus 11% in the placebo group [15] 
within 60 minutes after administration. Blood loss was 
388 ml lower in the sulprostone group (average blood 
loss 1062 ml) as compared to controls (average blood loss 
1450 mls). Unfortunately, treatment with sulprostone is 
not applicable in low resources settings because the drug 
is relatively expensive and needs to be stored refrigerated.
The prostaglandin E1 analogue misoprostol is inexpen­
sive and does no t need to be stored refrigerated. Therefore, 
it is of potential use in low-resource countries. In a recent 
study in which 54 patients with RP were randomised to 
misoprostol, oxytocin and placebo, administered through 
the umbilical cord [16], a significant reduction of MRP 
was reported for the misoprostol (43% MRP) compared 
to the oxytocin (80% MRP) and placebo (54% MRP) 
groups. When misoprostol was administered rectally in a 
group of 10 patients [17], it was reported to avoid MRP in 
7 patients and to reduce blood loss. Oral or sublingual 
administration of misoprostol, though potentially the 
fastest acting [18] and most practical, has not been stud­
ied in an effort to reduce MRP.
Misoprostol
Misoprostol is an prostaglandin E1-analogue with uterot- 
onic properties that can be administered orally, sublin­
gually, vaginally and rectally [19]. Sublingual 
administration of misoprostol achieves the highest serum 
peak concentration and takes the shortest time to reach 
the peak level, in comparison with other routes of admin­
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istration [18]. Misoprostol is cheap and stable at room 
temperature. Originally, misoprostol was introduced as 
treatment for peptic ulcers. It soon became obvious that it 
stimulates uterine contractions [20]. Misoprostol has 
been used to treat various obstetrical problems, including 
uterine atony, postpartum haemorrhage [21], induction 
of labour, and induction of abortion [19,20]. Misoprostol 
when given postpartum is known to cause only mild side 
effects (shivering and pyrexia) [19,22-24]. Misoprostol is 
a sustainable drug for use in developing countries for the 
treatment of various obstetrical complications [20] like 
postpartum haemorrhage, induction of labour and induc­
tion of abortion. It is registered in Tanzania for the pre­
vention and treatment of postpartum haemorrhage.
Study justification
Women in rural areas in resource-poor settings who 
deliver at home or in a village health care facility, and in 
whom the delivery is complicated by RP, have difficulty to 
reach appropriate medical help in time and have a consid­
erable chance to die because from post partum hemor­
rhage. Because preliminary evidence suggests that 
prostaglandins like misoprostol may expel the placenta 
and reduce blood loss in women with RP, a RCT is 
designed to compare sublingually administered misopr­
ostol with placebo to tests its effectiveness to reduce the 
need of MRP and blood transfusion in a low-resource set­
ting.
Aims of the trial
The aims of this randomised, double blind, placebo-con­
trolled trial is to assess if sublingual misoprostol reduces 
the need of Manual Removal of Placenta (MRP) and the 
am ount of blood loss in women with RP in a low resource 
setting. The primary outcome variable is reduction in the 
incidence of MRP and the secondary outcome variable is 
the reduction in the number of units of packed cells 
administered.
The primary hypothesis of this randomised trial is that the 
administration of misoprostol to women with RP reduces 
the num ber of women who need MRP. The secondary 
hypothesis is that misoprostol reduces the am ount of 
blood loss in women with RP, especially in those in 
whom the placenta is expelled by the intervention. Since 
measurement of blood loss during delivery is not always 
very reliable, we choose as secondary outcome variable 
both the measured am ount of blood loss and the number 
of administered packed cells.
Methods/Design  
Study Design
Multicentered randomised, double-blind, placebo-con­
trolled trial.
Participating hospitals &  approval
The study will be conducted in four rural hospitals in 
Southern Tanzania (the regional hospitals of Lindi and 
Mtwara regions and Ndanda and Nyangao mission hospi­
tals) and in the university teaching hospital in the capital 
Dar es Salaam. Approval for this study was obtained from 
the National Institute of Medical Research (NIMR), the 
Senate Research and Publication Committee of Muhim- 
bili University of Health and Allied Sciences and the 
Muhimbili National Hospital in Tanzania. A data m an­
agement safety board has been installed.
Inclusion criteria and trial entry
All labouring women will receive AMTSL and are eligible 
if 30 minutes after delivery of the infant the placenta has 
no t been expelled and were delivered of a baby of 1 kg or 
more or at a gestational age of 28 weeks or more. AMTSL 
is defined as administration of 5IU oxytocin and control­
led cord traction (CCT). If the placenta is delivered the 
uterus will be massaged.
Exclusion criteria
Women with one of the following conditions will be 
excluded from entering the trial:
* Haemoglobin concentration less than 100 g/l (6.2 
mmol/l)
* Blood loss more than 750 ml
* Pulse rate more than 120 beats per minute
* Diastolic blood pressure reduction after delivery 
more than 20 mmHg
Trial Entry
Eligible women will be identified in the labour ward at 20 
minutes after delivery of the infant. The bladder will be 
catheterised, an intravenous canula will be inserted and 
normal saline solution will be started, CCT will be per­
formed again and blood will be taken for cross-match and 
haemoglobin concentration. They will receive verbal and 
written information in Kiswahili about participation in 
the trial and will be asked to give their informed consent. 
The randomisation schedule uses balanced variable 
blocks; sealed envelopes containing both registration 
form and blinded study medication are present in the 
delivery room. Allocation will be in sequence of enrol­
m ent in each of the five labour wards. Each sealed envelop 
contains two identical capsules with either 800 micro­
gram misoprostol or placebo. The patient, the maternal 
care providers and the researchers are all blinded to the 
allocation. Women will enter the study after giving their 
informed consent at 30 minutes following the delivery of 
the infant, at which time the envelope will be opened and
Page 3 of 6
(page number not for citation purposes)
BMC Pregnancy and Childbirth 2009, 9:48 http://www.biomedcentral.eom/1471 -2393/9/48
the two capsules of study medication will be administered 
sublingually. Figure 1 depicts the flowchart for trial entry.
Study M edication & Treatment Schedules
After administration of the study medication, the doctor 
or midwife will perform CCT every ten minutes to check 
if the placenta has separated from the uterine wall. Vagi­
nal blood loss will be measured by weighing self absorb­
able mattresses. Blood loss exceeding 1500 ml will be 
considered as indication for emergency MRP. If the pla­
centa is not expelled 30 minutes after the administration 
of the study medication, the patient will undergo MRP.
Follow-up o f women in both treatment groups
All women enrolled in the study are followed up for 12­
24 hours. Blood pressure, pulse rate uterine contraction 
and vaginal blood loss are monitored, and the haemo­
globin concentration prior to discharge is recorded. 
W omen are receiving blood transfusion and and/or intra­
venous iron dextrane infusion, according to the hospitals 
guidelines, if needed. All women receive combined ferro- 
fumerate and folic acid tablets according to the national 
guideline on care for post partum women.
Study Endpoints
The primary study outcome is:
Manual removal of the placenta.
Figure!
Flowchart fo r tr ia l entry. AMTSL = Active management of third stage of labour. RP = retained placenta. CCT = controlled 
cord traction. Hb = Haemoglobin. BP = Blood pressure. MRP = Manual removal of placenta. Hb = haemoglobine.
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The secondary outcomes are:
* Measured post partum blood loss,
* Number of units of blood administered,
* Adverse outcome for the woman, including side-
effects from the study medication and number of
emergency MRP needed.
Sample Size
The primary endpoint of the study is manual removal of 
the placenta. For eligible women (with RP 30 minutes 
after delivery of the infant) the best estimate of MRP is 
44% at 60 minutes post partum. Using 2:1 misoprostol to 
placebo randomisation, a sample size of 117 women will 
be able to show a 40% reduction in MRP (5% level of sig­
nificance, two-tailed alpha, 80% power). Thus, 39 
patients will receive placebo and 78 will receive misopros­
tol.
Analysis and Reporting of Results
Baseline characteristics of all women enrolled in the study 
are documented and analysed in order to verify the 
absence of confounding differences in baseline variables 
between groups. Outcome comparisons for women will 
be analysed according to 'intention to treat'. Relative risks 
and 95% confidence intervals will be reported for the pri­
mary and secondary outcomes, and the number needed to 
treat to prevent one MRP will be calculated. A data m an­
agement safety board will check the data at regular inter­
vals.
Discussion
This is a protocol for RCT assessing the efficacy of sublin­
gual misoprostol in women with a RP 30 minutes after 
delivery of the infant. The trial is conducted in a low- 
resource setting in order to establish if misoprostol treat­
m ent of RP reduces maternal morbidity associated with 
retained placenta in such a setting. This study is partially 
carried out in an environment where communication is 
difficult and where people have little experience with con­
ducting research. During the research period we have to 
anticipate unforeseen difficulties like breakdown of 
equipment, loss of data or study medication and other 
unpredictable events.
When the hypotheses of the study, that misoprostol 
reduces the am ount of MRP and blood loss, is confirmed, 
it should have consequences for the basic obstetrical care 
in rural health centres in  developing countries. Misopros­
tol should then be made available to all health facilities 
and staff should be trained in administering the drugs cor­
rectly.
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